Global CellTherapy

Global Cell Therapy (GCT) is a South Korean biotechnology company focused on the development of innovative natural killer (NK) cell-based immunotherapies for the treatment of various cancers. The company utilizes a proprietary technology platform designed for the large-scale expansion and high-level activation of NK cells derived from peripheral blood. GCT's lead clinical candidate, GCT-101, is an autologous NK cell therapy currently being evaluated in Phase 1/2 clinical trials for its safety and efficacy against advanced solid tumors. By leveraging its specialized cell processing capabilities, GCT aims to provide more effective and accessible treatment options for patients with refractory or metastatic malignancies. The company is also exploring allogeneic off-the-shelf cell therapy products to broaden its therapeutic reach.